
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145876410.1021/acsomega.8b00805ArticleSynthesis of N-Fused Benzimidazole-4,7-diones
via Sequential Copper-Catalyzed
C–N Coupling/Cyclization and Oxidation Dao Pham Duy
Quang Ho Son Long †Cho Chan Sik *Department of Applied Chemistry, Kyungpook National University, 80 Daehakro, Bukgu, Daegu 41566, Republic
of Korea* E-mail: cscho@knu.ac.kr.25 05 2018 31 05 2018 3 5 5643 5653 25 04 2018 15 05 2018 Copyright © 2018 American Chemical Society2018American Chemical SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

2-(2-Bromovinyl)-
and 2-(2-bromoaryl)-benzimidazoles, including
their 4,7-dimethoxy analogs, react with primary amides by microwave
irradiation (or usual heating) in dimethylformamide in the presence
of a catalytic amount of CuI along with a base to give the corresponding
benzo[4,5]imidazo[1,2-c]-pyrimidines and -quinazolines
in good yields. Treatment of benzo[4,5]imidazo[1,2-c]-pyrimidines and -quinazolines having methoxy group on benzimidazole
moiety with aqueous ceric ammonium nitrate affords unprecedented N-fused
hybrid scaffolds, benzo[4,5]imidazo[1,2-c]-pyrimidin-6,9-diones
and -quinazoline-8,11-diones, respectively, in high yields.

document-id-old-9ao8b00805document-id-new-14ao-2018-00805zccc-price
==== Body
Introduction
It is known that N-fused
hybrid structures exhibit characteristic
biological activities that are not shown in each homonuclear scaffolds.
Pyrimidine- and quinazoline-fused benzimidazole hybrid scaffolds,
benzo[4,5]imidazo[1,2-c]-pyrimidines (Scheme 1, A) and -quinazolines
(Scheme 1, B), have been synthesized due to their intrinsic biological activities.1−3 We have also recently reported that 2-(2-bromovinyl)- and 2-(2-bromophenyl)-benzimidazoles
are coupled and cyclized with cyanamide in the presence of a copper
catalyst to give such N-fused hybrid scaffolds.4 In connection with this report, it is known that primary
amides can serve as building blocks for the construction of N-heterocycles
by a copper-catalyzed coupling and cyclization reaction.5,6 Ma and co-workers reported that N-substituted o-bromobenzamides react with primary amides in the presence of CuI
to give quinazolinones.7 While the present
work was being performed, such a similar coupling and cyclization
reaction leading to imidazo[1,2-c]quinazolines was
also exemplified by the reaction of 2-(2-bromoaryl)-1H-imidazoles and formamide under CuI catalysis.8 As part of our continuing studies directed toward transition-metal-catalyzed
synthesis of N-fused hybrid scaffolds,4,9 we provide
here a new synthetic method for benzo[4,5]imidazo[1,2-c]-pyrimidines and -quinazolines by copper-catalyzed coupling and
cyclization of 2-(2-bromovinyl)- and 2-(2-bromoaryl)-benzimidazoles
with primary amides as building blocks. In addition, this report also
shows the synthesis of unprecedented N-fused hybrid scaffolds, benzo[4,5]imidazo[1,2-c]pyrimidin-6,9-diones (Scheme 1, C) and benzo[4,5]imidazo[1,2-c]quinazoline-8,11-diones (Scheme 1, D), from methoxy-substituted A and B derivatives on benzimidzole moiety. To
the best of our knowledge, no reports are found for the synthesis
of C and D scaffolds. Only one example for
the synthesis of N-fused hybrid analogue of C, benzo[4,5]imidazo[1,2-a]pyrimidin-6,9-dione, is known.10 However, several [1,2-a]alicyclic ring-fused benzimidazolequinones
have been synthesized and tested for biological activity.11 Benzimidazole-based 1,4-quinone (1H-benzo[d]imidazole-4,7-dione)-containing compounds
has received pivotal attention in the development of bioreductive
quinone-based drugs due to a wide spectrum of biological activities,
such as anticancer, cytotoxic, antitumor, and antiproliferative activities.11,12

Scheme 1 N-Fused Hybrid Scaffolds
Results and Discussion
Treatment of 2-(2-bromovinyl)benzimidazole 1a with
equimolar amount of formamide (2a) in dimethylformamide
(DMF) at 110 °C for 24 h in the presence of CuI along with Cs2CO3 afforded 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (3a) in 31% isolated yield (Table 1, entry 1). It is
known that N-substituted o-bromobenzamides are effectively
coupled and cyclized with primary amides in the presence of CuI along
with additional amino acid to give quinazolinones.7 Higher yield of 3a was observed with further
addition of l-proline (L1) as ligand (Table 1, entry 2). The yield
of 3a gradually increased with an increase of the molar
ratio of 2a to 1a up to 2 (Table 1, entries 2–4). Other
ligands, such as glycine (L2), 2-picolinic acid (L3), and 1,10-phenanthroline (L4), combined with
CuI were not effective for the formation of 3a like l-proline (Table 1, entries 4–7). The reaction proceeded with other bases, such
as K2CO3, K3PO4, NaOtBu, and Bu3N, using CuI and l-proline, but the yield of 3a was generally lower
than that by the use of Cs2CO3 (Table 1, entries 8–11). Among
solvents examined under the employed conditions, DMF was shown to
be the solvent of choice (Table 1, entries 4, 12, and 13). Other copper catalysts, such
as CuBr, CuCl, or Cu powder, combined with l-proline showed
lower catalytic activity than CuI (Table 1, entries 14–16). However, the reaction
did not proceed at all toward 3a in the absence of copper
catalyst (Table 1,
entry 17). We have recently reported the synthesis of heterocycles
by copper-catalyzed coupling and cyclization under microwave irradiation
to increase the reaction rate and to obtain an acceptable yield of
product.4,9a,13 When 1a was treated with 2a in DMF at 110 °C
for 1 h in the presence of CuI/l-proline and Cs2CO3 under microwave irradiation (initial power, 100 W), 3a was obtained in 71% yield (Table 1, entry 18). Higher reaction temperature
up to 130 °C resulted in a slightly increased yield of 3a (Table 1, entry 19). As is the case for the usual heating conditions, lower
yield of 3a was observed in the absence of l-proline (Table 1,
entry 20).

Table 1 Optimization of Conditions for the
Reaction of 1a and 2aa
entry	[2a]/[1a]	Cu catalyst	ligand	base	solvent	yieldb (%)	
1	1	CuI	 	Cs2CO3	DMF	31	
2	1	CuI	L1	Cs2CO3	DMF	51	
3	1.5	CuI	L1	Cs2CO3	DMF	59	
4	2	CuI	L1	Cs2CO3	DMF	70	
5	2	CuI	L2	Cs2CO3	DMF	64	
6	2	CuI	L3	Cs2CO3	DMF	49	
7	2	CuI	L4	Cs2CO3	DMF	32	
8	2	CuI	L1	K2CO3	DMF	41	
9	2	CuI	L1	K3PO4	DMF	37	
10	2	CuI	L1	NaOtBu	DMF	51	
11	2	CuI	L1	Bu3N	DMF	28	
12	2	CuI	L1	Cs2CO3	DMSO	42	
13	2	CuI	L1	Cs2CO3	1,4-dioxane	11	
14	2	CuBr	L1	Cs2CO3	DMF	51	
15	2	CuCl	L1	Cs2CO3	DMF	41	
16	2	Cu powder	L1	Cs2CO3	DMF	43	
17	2	 	L1	Cs2CO3	DMF	0	
18c	2	CuI	L1	Cs2CO3	DMF	71	
19c,d	2	CuI	L1	Cs2CO3	DMF	78	
20c,d	2	CuI	 	Cs2CO3	DMF	64	
a Reaction
conditions: 1a (0.3 mmol), 2a (0.6 mmol),
Cu catalyst (0.03 mmol),
ligand (0.09 mmol), base (0.9 mmol), solvent (3 mL), 110 °C,
24 h, unless otherwise stated.

b Isolated yield.

c Under
microwave irradiation (100
W of initial power), 110 °C, 1 h, unless otherwise stated.

d At 130 °C.

Having optimized the reaction conditions
(condition A: entry 4
of Table 1; condition
B: entry 19 of Table 1), various 2-(2-bromovinyl)- and 2-(2-bromoaryl)-benzimidazoles 1 were subjected to the reaction with primary amides 2 to investigate the reaction scope, and several representative
results are summarized in Table 2. The coupling and cyclization of 1a with
primary amides 2b–d also proceeded
to give the corresponding benzo[4,5]imidazo[1,2-c]pyrimidines 3b–d in good yields.
Benzo[4,5]imidazo[1,2-c]pyrimidine 3e was also formed from 1b and 2a in similar
yields irrespective of methyl substituent on 1b. The
six-membered 2-(2-bromovinyl)benzimidazoles (1c and 1d) also reacted with 2a to give the corresponding
benzo[4,5]imidazo[1,2-c]pyrimidines (3f and 3g), irrespective of the presence of the methyl
and phenyl substituents on 1c and 1d. With
cyclic 2-(2-bromovinyl)benzimidazoles 1e–g having various ring sizes, the corresponding benzo[4,5]imidazo[1,2-c]pyrimidines 3h–j were
also produced in 54–80% yields and the yield decreased with
the increase in ring size. The coupling and cyclization of benzo-fused
2-(2-bromovinyl)benzimidazole 1h took place with 1a to give 5,6-dihydrobenzo[f]benzo[4,5]imidazo[1,2-c]quinazoline (3k) in 57% yield. The reaction
of acyclic 2-(2-bromovinyl)benzimidazoles (1i and 1j) with 2a also afforded the coupled and cyclized
products 3l and 3m in 53 and 51% yields,
respectively. Similar treatment of 2-(2-bromoaryl)benzimidazoles 1k–m with primary amides 2a–c under the employed conditions also afforded
the corresponding quinazoline-fused benzimidazoles 3n–r in 53–71% yields. As shown in Table 2, higher product yields
were observed under condition B compared to condition A.

Table 2 Cu-Catalyzed Coupling and Cyclization
of 1 with 2 Leading to 3a
a Reaction conditions: 1 (0.3 mmol), 2 (0.6 mmol) CuI (0.03 mmol), l-proline (0.09 mmol), Cs2CO3 (0.9 mmol),
and
DMF (3 mL). Condition A: 110 °C, 24 h. Condition B: 130 °C,
1 h, under microwave irradiation (100 W of initial power).

On the basis of the reaction of
2-(2-bromovinyl)- and 2-(2-bromoaryl)-benzimidazoles
with primary amides, the present protocol can be extended to the reaction
with 4,7-dimethoxy-substituted benzimidazole analogues. Table 3 shows several results for further
optimization with 2-(2-bromophenyl)-4,7-dimethoxy-1H-benzo[d]imidazole (4a) and 2a to realize the effective formation of quinazoline-fused dimethoxybenzimidazole 5. Similar treatment of 4a with 2a under condition B (Table 1, entry 19) afforded 5a in only 43% yield along
with concomitant formation of 4,7-dimethoxy-2-phenyl-1H-benzo[d]imidazole (6, 46% yield) by
debromination of 4a (Table 3, entry 1). When 4a was treated
in the absence of 2a under the employed conditions, 4a was recovered almost completely (99%). This result indicates
that formamide (2a) plays a significant role in debromination.
In contrast to the results from the reaction of 1a with 2a (Table 1, entries 1 and 2, 19 and 20), performing the reaction in the absence
of l-proline resulted in similar yield of 5a without the formation of debromination byproduct (Table 3, entry 2). Higher loading of
CuI was needed for an allowable yield of 5a (Table 3, entry 3). After
further tuning reaction variants, such as Cu catalyst, base, and solvent
(Table 3, entries 4–11),
the best result in terms of the yield of product 5a and
complete conversion of 4a was obtained with the standard
set of reaction conditions shown in entry 7 of Table 3.

Table 3 Optimization of Conditions
for the
Reaction of 4a and 2aa
entry	Cu catalyst	base	solvent	yieldb (%)	
1c,d	CuI	Cs2CO3	DMF	43	
2d	CuI	Cs2CO3	DMF	47	
3	CuI	Cs2CO3	DMF	63	
4	CuBr	Cs2CO3	DMF	59	
5	CuCl	Cs2CO3	DMF	51	
6	Cu powder	Cs2CO3	DMF	28	
7	CuI	K2CO3	DMF	81	
8	CuI	K3PO4	DMF	77	
9	CuI	NaOtBu	DMF	69	
10	CuI	K2CO3	DMSO	51	
11	CuI	K2CO3	1,4-dioxane	42	
a Reaction conditions: 4a (0.3 mmol), 2a (0.6
mmol), Cu catalyst (0.06 mmol),
base (0.9 mmol), solvent (3 mL), microwave irradiation (initial power,
100 W), 130 °C, 1 h, unless otherwise stated.

b Isolated yield.

c In the presence of l-proline
(0.09 mmol).

d CuI (0.03 mmol).

The coupling and cyclization
could be applied to many 4,7-dimethoxybenzimidazoles 4 with primary amides under the conditions shown in entry
7 of Table 3 (condition
C), and several representative results are summarized in Table 4. From the reaction
of 4a with an array of primary amides 2b–g, the corresponding quinazoline-fused 4,7-dimethoxybenzimidazoles 5b–g also invariably formed irrespective
of the identity of primary amides. 2-(2-Bromovinyl)-4,7-dimethoxybenzimidazole 4b was also readily coupled and cyclized with primary amides 2a–e to give the corresponding pyrimidine-fused
4,7-dimethoxybenzimidazoles 5h–l in
the range of 71–81% yields. As is the case for the reaction
of 1 with 2, cyclic 2-(2-bromovinyl)-4,7-dimethoxybenzimidazoles 4c–f having various ring sizes also reacted
with 2a to afford pyrimidine-fused 4,7-dimethoxybenzimidazoles 5m–p in similar yields. Acyclic 2-(2-bromovinyl)-4,7-dimethoxybenzimidazoles
(4g and 4h) were also reacted with 2a to give pyrimidine-fused 4,7-dimethoxybenzimidazoles (5q and 5r).

Table 4 Cu-Catalyzed Coupling
and Cyclization
of 4 with 2 Leading to 5a
a Reaction conditions: 4 (0.3 mmol), 6 (0.6 mmol) CuI (0.06 mmol), K2CO3 (0.9 mmol), DMF (3 mL), 130 °C, 1 h, under
microwave
irradiation (100 W of initial power).

As shown in Table 5, all quinazoline- and pyrimidine-fused dimethoxybenzimidazoles 5a–r could be converted into unprecedented
quinazoline- and pyrimidine-fused benzimidazolequinones 7a–r with 70–89% yields by treatment of
ceric ammonium nitrate (CAN) in aqueous acetonitrile.12a,12f,14−16

Table 5 CAN-Mediated Oxidation of 5–7a
a Reaction conditions: 5 (0.1 mmol), CAN (0.4 mmol), acetonitrile/H2O
(4 mL),
rt, 20 min.

The reaction
pathway seems to proceed via an initial formation
of C–N-coupled intermediate by copper-catalyzed Ullmann-type
coupling between 1 (or 4) and 2, followed by cyclization and dehydration.8,17 We
confirmed that a similar treatment of N-methyl-2-(2-bromophenyl)benzimidazole 8 with benzamide (2c) under the employed conditions
afforded C–N-coupled intermediate 9 in 70% yield
(Scheme 2).

Scheme 2 Conclusions
In summary, we have developed a new synthetic
method for benzo[4,5]imidazo[1,2-c]-pyrimidines and
-quinazolines by copper-catalyzed coupling
and cyclization of 2-(2-bromovinyl)- and 2-(2-bromoaryl)-benzimidazoles
with primary amides. Such scaffolds having methoxy group on benzimidzole
moiety could be transformed into unprecedented N-fused hybrid scaffolds,
benzo[4,5]imidazo[1,2-c]pyrimidin-6,9-diones and
benzo[4,5]imidazo[1,2-c]quinazoline-8,11-diones,
by treatment with aqueous ceric ammonium nitrate. Further challenges
on the synthesis of novel benzimidazole-based 1,4-quinone-containing
N-fused hybrid heterocyclic compounds using the present protocol are
expected.

Experimental Section
General Information
1H (400 and 500 MHz)
and 13C NMR (100 and 125 MHz) spectra were recorded in
CDCl3 or DMSO-d6. Melting points
were determined on a microscopic melting point apparatus. High-resolution
mass data were recorded by electronic ionization (HRMS-EI, magnetic
sector–electric sector double-focusing mass analyzer) at Korea
Basic Science Center, Daegu, Korea. All microwave reactions (CEM,
Discover LabMate) were carried out in sealed tube (5 mL), and maintenance
of the reaction temperature was monitored by an external infrared
sensor. Isolation of pure products was carried out by thin-layer (a
glass plate coated with Kieselgel 60 GF254, Merck) chromatography.
2-(2-Bromovinyl)benzimidazoles and 2-(2-bromoaryl)benzimidazoles were
prepared from the corresponding carboxylic acids (or aldehydes) and
1,2-phenylenediamines by literature procedures.3g,11a,18 Commercially available organic and inorganic
compounds were used without further purification.

General Procedure
for the Synthesis of 3 (Condition
A)
To a 5 mL screw-capped vial was added 1 (0.3
mmol) and 2 (0.6 mmol), together with CuI (0.006 g, 0.03
mmol), l-proline (0.010 g, 0.09 mmol), Cs2CO3 (0.293 g, 0.9 mmol), and DMF (3 mL). The reaction mixture
was stirred at 110 °C for 24 h. The mixture was then cooled to
room temperature and filtered through a short silica gel column (ethyl
acetate) to remove inorganic components. Removal of the solvent left
a crude mixture, which was separated by thin-layer chromatography
(TLC) (dichloromethane/MeOH = 99:1) to give 3.

General
Procedure for the Synthesis of 3 (Condition
B)
A 5 mL microwave reaction tube was charged with 1 (0.3 mmol) and 2 (0.6 mmol), together with
CuI (0.006 g, 0.03 mmol), l-proline (0.010 g, 0.09 mmol),
Cs2CO3 (0.293 g, 0.9 mmol), and DMF (3 mL).
The reaction mixture was heated to 130 °C for 1 h by microwave
irradiation at 100 W initial power. The mixture was then cooled to
room temperature and filtered through a short silica gel column (ethyl
acetate) to remove inorganic components. Removal of the solvent left
a crude mixture, which was separated by TLC (dichloromethane/MeOH
= 99:1) to give 3. Except for known 3n,193o,19 and 3p,3g all new products
were characterized spectroscopically.

1,2,3,4-Tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline
(3a)
Pale yellow solid (52 mg, 78%). Mp 204–206
°C. 1H NMR (400 MHz, CDCl3): δ 1.89–1.99
(m, 4H), 2.88–2.91 (m, 2H), 3.06–3.09 (m, 2H), 7.36–7.40
(m, 1H), 7.52–7.56 (m, 1H), 7.91–7.94 (m, 2H), 9.10
(s, 1H). 13C NMR (100 MHz, CDCl3): δ 21.7,
22.7, 23.5, 31.5, 110.6, 119.8, 120.2, 122.2, 126.8, 127.2, 135.9,
144.8, 148.4, 150.7. HRMS (EI) anal. calcd for C14H13N3 (M+): 223.1109. Found: 223.1108.

6-Methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (3b)
Pale yellow solid (47 mg,
66%). Mp 174–176 °C. 1H NMR (400 MHz, CDCl3): δ 1.84–1.87 (m, 4H), 2.76–2.77 (m,
2H), 2.98–2.99 (m, 2H), 3.02 (s, 3H), 7.26–7.30 (m,
1H), 7.44–7.48 (m, 1H), 7.86–7.92 (m, 2H). 13C NMR (100 MHz, CDCl3): δ 21.9, 22.8, 23.3, 23.7,
31.3, 114.5, 117.2, 120.0, 121. 9, 126.2, 128.7, 145.3, 147.6, 149.8,
150.1. HRMS (EI) anal. calcd for C15H15N3 (M+): 237.1266. Found: 237.1265.

6-Phenyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (3c)
Pale yellow solid
(64 mg,
71%). Mp 186–188 °C. 1H NMR (400 MHz, CDCl3): δ 1.94–2.02 (m, 4H), 2.92–2.95 (m,
2H), 3.13–3.16 (m, 2H), 6.67 (d, J = 8.3 Hz,
1H), 7.01–7.04 (m, 1H), 7.41–7.45 (m, 1H), 7.59–7.68
(m, 5H), 7.90 (d, J = 8.4 Hz, 1H). 13C
NMR (100 MHz, CDCl3): δ 21.9, 22.8, 23.5, 31.5, 114.7,
118.2, 119.8, 121.5, 126.2, 128.3, 128. 5, 129.4, 131.0, 134.3, 145.1,
148.8, 150.0, 150.4. HRMS (EI) anal. calcd for C20H17N3 (M+): 299.1422. Found: 299.1420.

6-Benzyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (3d)
Pale yellow solid (55 mg,
59%). Mp 190–192 °C. 1H NMR (400 MHz, CDCl3): δ 1.86–1.94 (m, 4H), 2.81–2.84 (m,
2H), 3.02–3.05 (m, 2H), 4.71 (s, 2H), 7.10–7.16 (m,
6H), 7.38–7.42 (m, 1H), 7.72 (d, J = 8.6 Hz,
1H), 7.84 (d, J = 8.4 Hz, 1H). 13C NMR
(100 MHz, CDCl3): δ 22.0, 22.8, 23.5, 31.4, 41.8,
115.0, 117.8, 119.9, 122.0, 126.2, 127.4, 127.9, 128.3, 129.9, 134.7,
145.3, 148.5, 150.1, 150.2. HRMS (EI) anal. calcd for C21H19N3 (M+): 313.1579. Found: 313.1579.

9,10-Dimethyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (3e)
Pale yellow solid
(57 mg, 76%). Mp 203–204 °C. 1H NMR (400 MHz,
CDCl3): δ 1.93–1.94 (m, 4H), 2.43 (s, 3H),
2.44 (s, 3H), 2.86–2.88 (m, 2H) 3.06 (s, 2H), 7.66 (d, J = 8.6 Hz, 2H), 9.01 (s, 1H). 13C NMR (100 MHz,
CDCl3): δ 20.7, 20.9, 21.8, 22.7, 23.4, 31.4, 110.6,
119.6, 120.0, 125.5, 131.7, 135.8, 136.1, 143.4, 147.9, 149.9. HRMS
(EI) anal. calcd for C16H17N3 (M+): 251.1422. Found: 251.1421.

2-Methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (3f)
Pale yellow solid
(43 mg,
61%). Mp 223–226 °C. 1H NMR (400 MHz, CDCl3): δ 1.11 (d, J = 6.6 Hz, 3H), 1.49–1.57
(m, 1H), 1.89–1.9 (m, 2H), 2.49–2.56 (m, 1H), 2.85–2.89
(m, 2H) 3.20–3.25 (m, 1H), 7.31–7.35 (m, 1H), 7.46–7.50
(m, 2H), 9.05 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 21.6, 28.1, 30.9, 31.4, 31.7, 110.7, 119.4, 120.3, 122.3,
126.8, 127.3, 136.0, 144.9, 148.4, 150.5. HRMS (EI) anal. calcd for
C15H15N3 (M+): 237.1266.
Found: 237.1265.

2-Phenyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (3g)
Pale yellow solid
(63 mg,
70%). Mp 201–203 °C. 1H NMR (400 MHz, CDCl3): δ 2.09–2.19 (m, 1H), 2.33–2.36 (m,
1H), 3.05–3.21 (m, 4H), 3.51–3.61 (m, 1H), 7.25–7.2
(m, 1H), 7.35–7.37 (m, 4H), 7.42–7.46 (m, 1H), 7.56–7.60
(m, 1H), 7.94–7.99 (m, 1H), 9.18 (s, 1H). 13C NMR
(100 MHz, CDCl3): δ 29.9, 30.9, 31.8, 39.1, 110.8,
119.4, 120.3, 122.4, 126.7, 126.9, 127.0, 127.3, 128.7, 136.3, 144.9,
145.1, 148.2, 150.2. HRMS (EI) anal. calcd for C20H17N3 (M+): 299.1422. Found: 299.1422.

2,3,4,5-Tetrahydro-1H-benzo[4,5]imidazo[1,2-c]cyclohepta[e]pyrimidine (3h)
Pale yellow solid (57 mg, 80%). Mp 212–214 °C. 1H NMR (400 MHz, CDCl3): δ 1.72–1.83
(m, 4H), 1.93–1.98 (m, 2H), 3.08–3.10 (m, 2H), 3.27–3.30
(m, 2H), 7.36–7.40 (m, 1H), 7.53–7.57 (m, 1H), 7.92–7.95
(m, 2H), 9.10 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 26.1, 26.6, 26.7, 32.6, 38.1, 110.9, 120.1, 122.0, 125.2,
127.0, 127.5, 135.6, 145.1, 149.2, 156.4. HRMS (EI) anal. calcd for
C15H15N3 (M+): 237.1266.
Found: 237.1264.

1,2,3,4,5,6-Hexahydrobenzo[4,5]imidazo[1,2-c]cycloocta[e]pyrimidine (3i)
Pale yellow solid (52 mg, 69%). Mp 205–208 °C. 1H NMR (400 MHz, CDCl3): δ 1.33–1.44
(m, 4H),
1.76–1.85 (m, 4H), 2.91–2.94 (m, 2H), 3.13–3.16
(m, 2H), 7.30–7.34 (m, 1H), 7.46–7.50 (m, 1H), 7.87
(d, J = 9.08 Hz, 2H), 9.08 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 25.8, 26.2, 26.6, 29.9,
30.2, 33.5, 110.8, 120.1, 122.1, 122.9, 126.9, 127.4, 136.5, 145.1,
148.51, 153.7. HRMS (EI) anal. calcd for C16H17N3 (M+): 251.1422. Found: 251.1422.

1,2,3,4,5,6,7,8,9,10-Decahydrobenzo[4,5]imidazo[1,2-c]cyclododeca[e]pyrimidine (3j)
Pale yellow solid (50 mg, 54%). Mp 202–204 °C. 1H NMR (400 MHz, CDCl3): δ 1.29–1.42
(m, 8H), 1.47–1.53 (m, 2H), 1.83–1.90 (m, 2H), 1.92–1.99
(m, 2H), 2.76–2.80 (m, 2H), 3.01–3.05 (m, 2H), 7.30–7.34
(m, 1H), 7.46–7.50 (m, 1H), 7.85–7.90 (m, 2H), 9.08
(s, 1H). 13C NMR (100 MHz, CDCl3): δ 22.6,
23.1, 24.5, 25.5, 25.8, 26.0, 26.8, 27.0, 30.8, 110.7, 120.2, 122.1,
122.9, 126.7, 127.1, 136.2, 145.0, 149.1, 153.4. HRMS (EI) anal. calcd
for C20H25N3 (M+): 307.2048.
Found: 307.2051.

5,6-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-c]quinazoline (3k)
Pale yellow solid
(46 mg, 57%). Mp 191–193 °C. 1H NMR (400 MHz,
CDCl3): δ 3.07–3.11 (m, 2H), 3.15–3.20
(m, 2H), 7.28–7.44 (m, 2H), 7.45–7.49 (m, 2H), 7.60–7.64
(m, 2H), 9.22 (s, 1H), 9.29 (d, J = 7.6 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ 28.3, 30.8, 110.7,
117.6, 120.6, 122.5, 126.7, 127.1, 127.3, 127.8, 128.7, 128.8, 130.3,
136.5, 136.9, 145.3, 146.0, 151.8. HRMS (EI) anal. calcd for C18H18N3 (M+): 271.1109. Found:
271.1111.

4-Methyl-3-phenylbenzo[4,5]imidazo[1,2-c]pyrimidine
(3l)
Pale yellow solid (41 mg, 53%). Mp 234–236
°C. 1H NMR (500 MHz, CDCl3): δ 2.18
(s, 3H), 6.52 (d, J = 8.5 Hz, 1H), 7.24–7.27
(m, 1H), 7.70–7.73 (m, 1H), 7.74–7.76 (m, 2H), 7.98–8.03
(m, 3H), 8.25 (d, J = 8.3 Hz, 1H), 9.03 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 14.5, 110.5, 110.8,
119.4, 120.3, 124.7, 126.6, 127.5, 129.2, 129.9, 130.6, 140.9, 142.2,
147.2, 154.2. HRMS (EI) anal. calcd for C17H13N3 (M+): 259.1109. Found: 259.1111.

3,4-Diphenylbenzo[4,5]imidazo[1,2-c]pyrimidine
(3m)
Pale yellow solid (49 mg, 51%). Mp 262–264
°C. 1H NMR (500 MHz, CDCl3): δ 7.12–7.14
(m, 4H), 7.17–7.19 (m, 3H), 7.20–7.24 (m, 2H), 7.30–7.32
(m, 3H), 7.52–7.55 (m, 1H), 8.30–8.32 (m, 1H), 9.33
(s, 1H). 13C NMR (125 MHz, CDCl3): δ 110.6,
120.7, 121.4, 122.0, 126.4, 126.9, 127.9, 128.1, 128.8, 129.7, 130.2,
132.7, 136.1, 137.8, 145.3, 150.2, 163.4. HRMS (EI) anal. calcd for
C22H15N3 (M+): 321.1266.
Found: 321.1267.

Benzo[4,5]imidazo[1,2-c]quinazoline
(3n)19
Pale yellow
solid
(47 mg, 71%). Mp 245–247 °C (lit.2 247–249 °C). 1H NMR (500 MHz, CDCl3): δ 7.40–7.43 (m, 1H), 7.47–7.51 (m, 1H), 7.56–7.60
(m, 2H), 7.68–7.72 (m, 1H), 7.96 (d, J = 8.0
Hz, 1H), 8.75 (dd, J = 7.8 and 0.8 Hz, 1H), 8.78
(d, J = 8.3 Hz, 1H), 9.17 (s, 1H). 13C
NMR (125 MHz, CDCl3): δ 110.2, 114.4, 119.1, 122.4,
123.2, 123.8, 124.4, 125.1, 128.2, 131.8, 143.9, 144.7, 146.5, 148.5.

6-Methylbenzo[4,5]imidazo[1,2-c]quinazoline
(3o)19
Pale yellow
solid (43 mg, 61%). Mp 176–177 °C (lit.2 177–179 °C). 1H NMR (500 MHz, CDCl3): δ 3.13 (s, 3H), 7.36–7.39 (m, 1H), 7.52–7.57
(m, 1H), 7.61–7.65 (m, 1H), 7.73–7.77 (m, 1H), 7.83
(d, J = 8.0 Hz, 1H), 7.93–7.97 (m, 2H), 8.64–8.65
(m, 1H). 13C NMR (125 MHz, CDCl3): δ 24.2,
114.4, 118.1, 120.2, 123.8, 124.4, 125.1, 127.3, 127.6, 129.2, 131.8,
142.2, 144.7, 147.5, 148.5.

6-Phenylbenzo[4,5]imidazo[1,2-c]quinazoline
(3p)3g
Pale yellow
solid (61 mg, 69%). Mp 227–228 °C (lit.3 230–231). 1H NMR (500 MHz, CDCl3): δ 6.60 (d, J = 8.3 Hz, 1H), 7.17–7.20
(m, 2H), 7.45–7.48 (m, 1H), 7.59–7.63 (m, 2H), 7.68–7.71
(m, 3H), 7.77–7.81 (m, 2H), 7.95–8.00 (m, 2H), 8.73
(dd, J = 7.8 and 0.8 Hz, 1H). 13C NMR
(125 MHz, CDCl3): δ 114.5, 118.2, 120.2, 122.5, 123.3,
124.5, 125.2, 128.2, 128.4, 128.6, 129.3, 131.1, 132.0, 134.2, 142.1,
144.0, 148.1, 148.6.

2-Fluorobenzo[4,5]imidazo[1,2-c]quinazoline
(3q)
Pale yellow solid (38 mg, 53%). Mp 268–271
°C. 1H NMR (500 MHz, CDCl3): δ 7.51–7.54
(m, 2H), 7.59–7.63 (m, 1H), 7.99–8.04 (m, 3H), 8.32
(dd, J = 8.4 and 2.9 Hz, 1H), 9.13 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 109.6 (d, J = 24.4 Hz), 110.2, 113.7 (d, J = 23.6
Hz), 120.3, 120.5, 123.4, 123.7, 126.4, 130.8 (d, J = 8.1 Hz), 131.0 (d, J = 9.1 Hz), 135.5 (d, J = 2.6 Hz), 139.2, 144.0, 161.9 (d, J =247.7
Hz). HRMS (EI) anal. calcd for C14H8FN3 (M+): 237.0702. Found: 237.0704.

2,3-Dimethoxybenzo[4,5]imidazo[1,2-c]quinazoline
(3r)
White solid (54 mg, 64%). Mp 227–229
°C. 1H NMR (500 MHz, CDCl3): δ 3.92
(s, 3H), 3.94 (s, 3H), 7.13 (s, 1H), 7.32–7.35 (m, 1H), 7.59
(s, 1H), 7.66–7.70 (m, 1H), 7.75 (dd, J =
7.8 and 1.5 Hz, 1H), 9.18 (d, J = 8.7 Hz, 1H), 9.35
(s, 1H). 13C NMR (125 MHz, CDCl3): δ 56.5,
57.1, 107.5, 107.8, 121.3, 122.5, 123.3, 127.0, 131.4, 136.1, 138.8,
140.3, 143.3, 149.1, 152.3, 160.6. HRMS (EI) anal. calcd for C16H13N3O2 (M+):
279.1008. Found: 279.1009.

General Procedure for the
Synthesis of 5 (Condition
C)
A 5 mL microwave reaction tube was charged with 4 (0.3 mmol) and 2 (0.6 mmol), together with
CuI (0.011 g, 0.06 mmol), K2CO3 (0.124 g, 0.9
mmol), and DMF (3 mL). The reaction mixture was heated to 130 °C
for 1 h by microwave irradiation at 100 W initial power. The mixture
was then cooled to room temperature and filtered through a short silica
gel column (ethyl acetate) to remove inorganic components. Removal
of the solvent left a crude mixture, which was separated by TLC (hexane/EA
= 2:1) to give 5.

8,11-Dimethoxybenzo[4,5]imidazo[1,2-c]quinazoline
(5a)
Pale yellow solid (23 mg, 81%). Mp 190–193
°C. 1H NMR (500 MHz, CDCl3): δ 4.02
(s, 6H), 7.00 (s, 2H), 7.36–7.40 (m, 1H), 7.52–7.56
(m, 1H), 7.91–7.94 (m, 2H), 9.10 (s, 1H). 13C NMR
(125 MHz, CDCl3): δ 55.2, 110.2, 119.5, 120.2, 124.1,
126.6, 128.4, 128.5, 131.4, 132.9, 135.5, 135.2, 142.4, 145.7. HRMS
(EI) anal. calcd for C16H13N3O2 (M+): 279.1008. Found: 279.1009.

8,11-Dimethoxy-6-methylbenzo[4,5]imidazo[1,2-c]quinazoline (5b)
Pale yellow solid
(63 mg,
72%). Mp 188–190 °C. 1H NMR (500 MHz, CDCl3): δ 1.25 (s, 3H), 4.00 (s, 6H), 6.64 (s, 2H), 6.93–6.96
(m, 1H), 7.13 (dd, J = 8.3 Hz, 1H), 7.33–7.37
(m, 1H), 7.60 (dd, J = 7.8 and 1.5 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ 29.7, 56.5, 104.1,
112.0, 116.0, 118.1, 119.0, 124.5, 129.0, 131.8, 137.1, 138.7, 139.4,
150.1, 158.7. HRMS (EI) anal. calcd for C17H15N3O2 (M+): 293.1164. Found: 293.1166.

8,11-Dimethoxy-6-phenylbenzo[4,5]imidazo[1,2-c]quinazoline
(5c)
Pale yellow solid (88 mg,
83%). Mp 214–217 °C. 1H NMR (500 MHz, CDCl3): δ 3.97 (s, 3H), 4.09 (s, 3H), 6.64–6.68 (m,
2H), 7.18–7.21 (m, 1H), 7.48–7.52 (m, 1H), 7.54–7.58
(m, 3H), 7.74 (dd, J = 7.9 and 1.4 Hz, 1H), 8.49–8.51
(m, 2H), 9.10 (dd, J = 8.5 and 1.0 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): δ
55.8, 56.1, 102.6, 104.2, 115.6, 119.8, 123.0, 124.9, 127.7, 127.8,
128.8, 130.6, 132.1, 133.3, 134.3, 138.3, 140.4, 145.0, 149.7, 164.7.
HRMS (EI) anal. calcd for C22H17N3O2 (M+): 355.1321. Found: 355.1318.

6-Benzyl-8,11-dimethoxybenzo[4,5]imidazo[1,2-c]quinazoline (5d)
Pale yellow solid
(95 mg,
86%). Mp 210–212 °C. 1H NMR (500 MHz, CDCl3): δ 3.86 (s, 2H), 3.95 (s, 3H), 4.08 (s, 3H), 6.66
(s, 2H), 7.04–7.07 (m, 1H), 7.18–7.21 (m, 1H), 7.25–7.28
(m, 2H), 7.34–7.37 (m, 1H), 7.60–7.63 (m, 3H), 8.73
(dd, J = 8.4 and 0.9 Hz, 1H). 13C NMR
(125 MHz, CDCl3): δ 46.4, 55.8, 56.1, 102.6, 104.2,
115.5, 116.8, 121.2, 122.8, 125.8, 126.9, 128.6, 129.4, 129.5, 130.9,
135.4, 136.9, 138.6, 149.0, 164.4, 170.4. HRMS (EI) anal. calcd for
C23H19N3O2 (M+): 369.1477. Found: 369.1474.

8,11-Dimethoxy-6-propylbenzo[4,5]imidazo[1,2-c]quinazoline (5e)
Pale yellow solid
(76 mg,
79%). Mp 206–209 °C. 1H NMR (500 MHz, CDCl3): δ 0.97 (t, J = 7.4 Hz, 3H), 1.83–1.90
(m, 2H), 2.46–2.49 (m, 2H), 3.88 (s, 6H), 6.53 (s, 2H), 6.94–6.97
(m, 1H), 7.20–7.23 (m, 1H), 7.71 (dd, J =
7.9, 1.4 Hz, 1H), 8.65 (dd, J = 8.4, 0.7 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ 14.0, 19.1, 40.9,
55.9, 56.2, 103.2, 103.6, 115.7, 121.4, 122.8, 126.2, 127.1, 128.9,
130.4, 130.7, 138.5, 149.2, 149.9, 173.0. HRMS (EI) anal. calcd for
C19H19N3O2 (M+): 321.1477. Found: 321.1476.

8,11-Dimethoxy-6-(pyridin-3-yl)benzo[4,5]imidazo[1,2-c]quinazoline (5f)
Pale yellow solid
(79 mg, 74%). Mp 251–254 °C. 1H NMR (500 MHz,
CDCl3): δ 3.68 (s, 3H), 4.00 (s, 3H), 6.42–6.44
(m, 1H), 6.60 (s, 2H), 7.00–7.07 (m, 2H), 7.24–7.28
(m, 2H), 7.29–7.32 (m, 1H), 7.44–7.47 (m, 1H), 7.64–7.66
(m, 1H). 13C NMR (125 MHz, CDCl3): δ 55.9,
56.0, 102.2, 104.3, 121.4, 124.1, 125.7, 126.6, 127.0, 127.2, 127.5,
125.5, 131.3, 131.6, 132.4, 132.5, 132.7, 137.4, 141.6, 146.2, 151.8.
HRMS (EI) anal. calcd for C21H16N4O2 (M+): 356.1273. Found: 356.1275.

8,11-Dimethoxy-6-(thiophen-2-yl)benzo[4,5]imidazo[1,2-c]quinazoline (5g)
Pale yellow solid
(78 mg, 72%). Mp 233–236 °C. 1H NMR (500 MHz,
DMSO-d6): δ 3.64 (s, 3H), 3.90 (s,
3H), 6.39 (dd, J = 7.7 and 1.6 Hz, 1H) 6.67 (d, J = 8.7 Hz, 1H), 6.72 (d, J = 8.7 Hz, 1H),
7.11–7.14 (m, 1H), 7.16–7.20 (m, 1H), 7.42–7.45
(m, 1H), 7.53 (dd, J = 7.9 and 1.3 Hz, 1H), 7.77–7.79
(m, 1H). 13C NMR (125 MHz, DMSO-d6): δ 55.8, 56.2, 103.2, 104.9, 120.7, 123.3, 126.8,
127.8, 128.0, 129.1, 131.1, 132.0, 132.4, 132.8, 134.3, 136.5, 141.0,
145.7, 150.9, 162.3. HRMS (EI) anal. calcd for C20H15N3O2S (M+): 361.0885. Found:
361.0887

8,11-Dimethoxy-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (5h)
Pale yellow solid
(65 mg, 76%). Mp 191–193 °C. 1H NMR (500 MHz,
CDCl3): δ 1.88–1.98 (m, 4H), 2.88–2.91
(m, 2H), 3.12–3.14 (m, 2H), 4.03 (s, 3H), 4.05 (s, 3H), 6.70
(d, J = 8.6 Hz, 1H), 6.81 (d, J =
8.6 Hz, 1H), 9.55 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 21.6, 22.6, 23.3, 31.3, 56.0, 102.1, 105.2, 118.0, 119.6,
136.6, 138.5, 143.0, 145.4, 147.5, 149.6. HRMS (EI) anal. calcd for
C16H17N3O2 (M+): 283.1321. Found: 283.1318.

8,11-Dimethoxy-6-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (5i)
Pale yellow solid
(63 mg, 71%). Mp 179–181 °C. 1H NMR (500 MHz,
CDCl3): δ 1.14 (s, 3H), 1.89–1.98 (m, 4H),
2.88–2.91 (m, 2H), 3.12–3.14 (m, 2H), 4.03 (s. 3H),
4.05 (s, 3H), 6.70 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.6 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ 18.8, 21.6, 22.6, 23.3, 31.3, 56.0, 56.2, 102.1, 105.2,
118.0, 119.6, 136.6, 138.5, 143.0, 145.4, 147.4, 149.6. HRMS (EI)
anal. calcd for C17H19N3O2 (M+): 297.1477. Found: 297.1475.

8,11-Dimethoxy-6-phenyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (5j)
Pale yellow solid
(82 mg, 76%). Mp 186–188 °C. 1H NMR (500 MHz,
CDCl3): δ 1.97–2.07 (m, 4H), 2.97–2.99
(m, 2H), 3.20–3.23 (m, 2H), 3.96 (s, 3H), 4.00 (s, 3H), 6.61
(d, J = 8.6 Hz, 1H), 6.79 (d, J =
8.6 Hz, 1H), 7.00–7.07 (m, 2H), 7.24–7.28 (m, 2H), 7.29–7.32
(m, 1H). 13C NMR (125 MHz, CDCl3): δ 21.6,
22.6, 23.3, 31.3, 55.8, 56.1, 102.6, 104.2, 119.9, 127.7, 127.9, 128.8,
130.6, 132.2, 133.3, 134.3, 138.4, 140.4, 145.1, 149.7. HRMS (EI)
anal. calcd for C22H21N3O2 (M+): 359.1634. Found: 359.1633.

6-Benzyl-8,11-dimethoxy-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (5k)
Pale yellow solid
(91 mg, 81%). Mp 193–196 °C. 1H NMR (500 MHz,
CDCl3): δ 1.95–2.05 (m, 4H), 2.95–2.97
(m, 2H), 3.18–3.21 (m, 2H), 3.92 (s, 2H), 4.10 (s, 3H), 4.11
(s, 3H), 6.76 (d, J = 8.6 Hz, 1H), 6.88 (d, J = 8.6 Hz, 1H), 7.24–7.27 (m, 1H), 7.31–7.34
(m, 2H), 7.66–7.69 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 22.6, 23.6, 24.3, 32.3, 45.9, 55.6, 56.2, 103.1,
106.2, 115.0, 120.7, 122.3, 125.3, 126.4, 128.1, 129.0, 130.4, 135.0,
138.1. 148.5, 169.9. HRMS (EI) anal. calcd for C22H21N3O2 (M+): 373.1790. Found:
373.1792.

8,11-Dimethoxy-6-propyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (5l)
Pale yellow solid
(76 mg, 78%). Mp 197–199 °C. 1H NMR (500 MHz,
CDCl3): δ 0.91 (t, J = 7.4, 3H),
1.62–1.70 (m, 2H), 1.81–1.89 (m, 4H), 2.41–2.44
(m, 2H), 2.79–2.82 (m, 2H), 3.03–3.05 (m, 2H), 3.94
(s, 3H), 3.95 (s, 3H), 6.61 (d, J = 8.6 Hz, 1H),
6.72 (d, J = 8.6 Hz, 1H). 13C NMR (125
MHz, CDCl3): δ 14.0, 19.1, 21.6, 22.6, 23.3, 31.3,
40.9, 55.9, 56.2, 103.2, 103.6, 121.4, 122.8, 126.2, 127.1, 128.9,
130.7, 138.5, 149.2. HRMS (EI) anal. calcd for C19H23N3O2 (M+): 325.1790. Found:
325.1791.

8,11-Dimethoxy-2-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline (5m)
Pale yellow solid
(62 mg, 70%). Mp 173–176 °C. 1H NMR (500 MHz,
CDCl3): δ 1.10 (d, J = 5.9 Hz, 3H),
1.45–1.52 (m, 1H), 1.88–1.96 (m, 2H), 2.41–2.45
(m, 1H), 2.80–2.85 (m, 2H), 3.15–3.22 (m, 1H), 3.92
(s, 3H), 4.00 (s, 3H), 6.84 (d, J = 8.5 Hz, 1H),
6.93 (d, J = 8.5 Hz, 1H), 9.48 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 21.1, 27.0, 29.9, 30.4,
30.8, 55.8, 56.0, 102.7, 106.6, 117.8, 120.0, 135.5, 138.2, 142.5,
144.5, 145.7, 148.9. HRMS (EI) anal. calcd for C17H19N3O2 (M+): 297.1477. Found:
297.1474.

9,12-Dimethoxy-2,3,4,5-tetrahydro-1H-benzo[4,5]imidazo[1,2-c]cyclohepta[e]pyrimidine (5n)
Pale yellow solid
(73 mg, 82%). Mp 194–196 °C. 1H NMR (500 MHz,
CDCl3): δ 1.74–1.78
(m, 2H), 1.90–1.99 (m, 4H), 2.87–2.89 (m, 2H), 3.57–3.59
(m, 2H), 3.96 (s, 3H), 4.05 (s, 3H), 6.65 (d, J =
8.6 Hz, 1H), 6.85 (d, J = 8.6 Hz, 1H), 9.17 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 25.1, 27.4, 30.7,
32.0, 34.0, 56.3, 56.5, 102.0, 105.8, 118.8, 122.7, 132.5, 136.3,
139.8, 145.5, 148.1, 150.2. HRMS (EI) anal. calcd for C17H19N3O2 (M+): 297.1477.
Found: 297.1479.

10,13-Dimethoxy-1,2,3,4,5,6-hexahydrobenzo[4,5]imidazo[1,2-c]cycloocta[e]pyrimidine (5o)
Pale yellow solid (74 mg, 79%). Mp 210–212 °C. 1H NMR (500 MHz, CDCl3): δ 1.33–1.37
(m, 2H), 1.44–1.48 (m, 2H), 1.72–1.77 (m, 2H), 1.88–1.92
(m, 2H), 2.79–2.82 (m, 2H), 3.65–3.67 (m, 2H), 3.93
(s, 3H), 4.03 (s, 3H), 6.66 (d, J = 8.7 Hz, 1H),
6.82 (d, J = 8.7 Hz, 1H), 9.14 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 25.8, 26.1, 29.1, 29.5,
29.7, 31.8, 56.0, 56.3, 102.2, 105.4, 118.8, 119.8, 132.0, 135.5,
139.8, 144.8, 145.4, 150.5. HRMS (EI) anal. calcd for C18H21N3O2 (M+): 311.1634.
Found: 311.1631.

14,17-Dimethoxy-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[4,5]imidazo[1,2-c]cyclododeca[e]pyrimidine (5p)
Pale yellow solid (72 mg, 65%). Mp 199–202 °C. 1H NMR (500 MHz, CDCl3): δ 1.35–1.47
(m, 8H), 1.51–1.59 (m, 4H), 1.61–1.69 (m, 2H), 1.78–1.83
(m, 2H), 2.79–2.82 (m, 2H), 3.65–3.68 (m, 2H), 3.98
(s, 3H), 4.06 (s, 3H), 6.72 (d, J = 8.7 Hz, 1H),
6.87 (d, J = 8.7 Hz, 1H), 9.27 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 21.9, 22.8, 24.6, 24.7,
25.5, 25.9, 26.5, 27.0, 28.2, 29.7, 56.0, 56.4, 102.3, 105.4, 119.3,
119.5, 130.1, 134.0, 138.0, 143.1, 143.3, 149.6. HRMS (EI) anal. calcd
for C22H29N3O2 (M+): 367.2260. Found: 367.2261.

6,9-Dimethoxy-4-methyl-3-phenylbenzo[4,5]imidazo[1,2-c]pyrimidine (5q)
Pale yellow solid
(65 mg, 68%). Mp 219–221 °C. 1H NMR (500 MHz,
CDCl3): δ 2.14 (s, 3H), 3.94 (s, 3H), 4.05 (s, 3H),
6.37 (d, J = 8.6 Hz, 1H), 6.78 (d, J = 8.6 Hz, 1H), 7.31–7.34 (m, 2H), 7.51–7.53 (m, 3H),
9.37 (s, 1H). 13C NMR (125 MHz, CDCl3): δ
15.9, 55.7, 56.4, 101.7, 105.7, 115.5, 118.6, 128.2, 128.3, 129.2,
130.6, 132.8, 137.1, 140.4, 142.2, 146.0, 152.4. HRMS (EI) anal. calcd
for C19H17N3O2 (M+): 319.1321. Found: 319.1319.

6,9-Dimethoxy-3,4-diphenylbenzo[4,5]imidazo[1,2-c]pyrimidine (5r)
Pale yellow solid
(80 mg,
70%). Mp 211–212 °C. 1H NMR (500 MHz, CDCl3): δ 4.02 (s, 3H), 4.09 (s, 3H), 6.68 (d, J = 8.6 Hz, 1H), 6.85 (d, J = 8.6 Hz, 1H), 7.25–7.28
(m, 4H), 7.31–7.37 (m, 4H), 7.51–7.53 (m, 2H), 9.79
(s, 1H). 13C NMR (125 MHz, CDCl3): δ 56.3,
57.4, 102.0, 107.2, 118.1, 121.7, 128.2. 129.1, 129.9, 130.3, 130.6,
136.4, 136.9, 137.8, 138.4, 143.9, 146.1, 149.6, 162.7. HRMS (EI)
anal. calcd for C24H19N3O2 (M+): 381.1477. Found: 381.1474.

4,7-Dimethoxy-2-phenyl-1H-benzo[d]imidazole (6)
White solid (37 mg, 48%). Mp
223–225 °C. 1H NMR (500 MHz, CDCl3): δ 3.88 (s, 6H), 6.63 (s, 2H), 7.72–7.76 (m, 3H),
8.07–8.11 (m, 2H). 13C NMR (125 MHz, DMSO): δ
55.9, 103.0, 125.4, 129.1, 130.1, 130.4, 131.0, 147.1. HRMS (EI) anal.
calcd for C15H14N2O2 (M+): 254.1055. Found: 254.1056.

General Procedure for the
Oxidation of 5–710,12
To a stirred solution of 5 (0.1 mmol) in acetonitrile/H2O (7:3, 2 mL) in
ice bath was added dropwise a solution of ceric ammonium nitrate (0.4
mmol) in acetonitrile/H2O (9:1, 2 mL). The reaction mixture
was stirred for 20 min at room temperature, during which time the
color turned brown. The reaction mixture was poured into cold water
and then extracted with ethyl acetate (40 mL). Removal of the solvent
and recrystallization from dichloromethane and hexane mixture gave 7.

Benzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione
(7a)
Brown solid (21 mg, 84%). Mp 216–219
°C. 1H NMR (500 MHz, DMSO-d6): δ 7.11 (s, 2H), 7.34–7.38 (m, 1H), 7.50–7.54
(m, 1H), 7.89–7.92 (m, 2H), 9.08 (s, 1H). 13C NMR
(125 MHz, DMSO-d6): δ 119.5, 120.2,
124.1, 126.6, 128.4, 128.5, 131.4, 132.8, 135.6, 136.4, 142.2, 179.7,
182.8. HRMS (EI) anal. calcd for C14H7N3O2 (M+): 249.0538. Found: 249.0540.

6-Methylbenzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione
(7b)
Brown solid (23 mg, 86%). Mp 202–205
°C. 1H NMR (500 MHz, DMSO-d6): δ 2.00 (s, 3H), 6.52 (d, J = 8.8 Hz, 1H),
6.57 (d, J = 8.8 Hz, 1H), 6.79–6.82 (m, 1H),
6.93 (d, J = 7.8 Hz, 1H), 7.09–7.12 (m, 1H),
7.86 (dd, J = 7.9 Hz and 1.1 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): δ 10.9,
113.4, 118.9, 122.4, 123.1, 123.7, 123.8, 124.2, 128.4, 130.6, 131.8,
140.9, 146.9, 178.9, 179.9. HRMS (EI) anal. calcd for C15H9N3O2 (M+): 263.0695.
Found: 263.0693.

6-Phenylbenzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione
(7c)
Brown solid (26 mg, 81%). Mp 239–241
°C. 1H NMR (500 MHz, DMSO-d6): δ 6.91 (d, J = 10.3 Hz, 1H), 7.00 (d, J = 10.3 Hz, 1H), 7.23–7.26 (m, 1H). 7.54–757
(m, 1H), 7.59–7.64 (m, 3H), 7.80 (dd, J =
7.9, 1.4 Hz, 1H), 8.54–8.56 (m, 2H), 9.16 (dd, J = 8.5, 1.0 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): δ 119.9, 122.2, 123.0, 124.9, 127.7, 127.9,
128.8, 130.6, 132.2, 133.3, 134.3, 138.4, 140.4, 145.1, 149.7, 164.7,
178.8, 180.9. HRMS (EI) anal. calcd for C20H11N3O2 (M+): 325.0851. Found: 325.0852.

6-Benzylbenzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione
(7d)
Brown solid (27 mg, 79%). Mp 250–253
°C. 1H NMR (500 MHz, DMSO-d6): δ 3.87 (s, 2H), 6.68 (d, J = 10.3 Hz, 1H),
6.73 (d, J = 10.3 Hz, 1H), 7.05–7.09 (m, 1H).
7.19–7.22 (m, 1H), 7.26–7.29 (m, 2H), 7.35–7.38
(m, 1H), 7.61–7.64 (m, 3H), 8.73–8.75 (m, 1H). 13C NMR (125 MHz, DMSO-d6): δ
45.7, 114.8, 116.2, 120.5, 122.2, 125.1, 126.2, 127.9, 128.7, 128.8,
130.2, 134.8, 136.3, 137.9, 148.3, 163.8, 169.7, 178.1, 182.8. HRMS
(EI) anal. calcd for C21H13N3O2 (M+): 339.1008. Found: 339.1009.

6-Propylbenzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione
(7e)
Brown solid (26 mg, 88%). Mp 232–235
°C. 1H NMR (500 MHz, DMSO-d6): δ 0.96 (t, J = 7.4 Hz, 3H), 1.82–1.89
(m, 2H), 2.35–2.39 (2, 2H), 6.53 (d, J = 10.4
Hz, 1H), 6.71 (d, J = 10.4 Hz, 1H), 6.93–6.96
(m, 1H), 7.19–7.22 (m, 1H), 7.70 (dd, J =
7.9, 1.4 Hz, 1H), 8.64 (dd, J = 8.4, 0.7 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): δ
12.2, 17.3, 34.8, 119.6, 121.0, 124.4, 125.3, 126.7, 127.1, 128.6,
128.9, 136.7, 147.4, 148.1, 171.2, 179.6, 181.1. HRMS (EI) anal. calcd
for C17H13N3O2 (M+): 291.1008. Found: 291.1006.

6-(Pyridin-3-yl)benzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione
(7f)
Brown solid (26 mg, 80%). Mp 278–280
°C. 1H NMR (500 MHz, DMSO-d6): δ 6.42–6.44 (m, 1H), 6.65 (d, J =
10.3 Hz, 1H), 6.83 (d, J = 10.3 Hz, 1H), 7.00–7.07
(m, 2H), 7.24–7.28 (m, 2H), 7.29–7.32 (m, 1H), 7.44–7.47
(m, 1H), 7.64–7.66 (m, 1H). 13C NMR (125 MHz, DMSO-d6): δ 122.1, 124.8, 126.4, 127.3, 127.7,
127.9, 128.2, 129.2, 132.0, 133.1, 133.2, 133.4, 138.1, 142.3, 146.9,
152.5, 178.3, 180.3. HRMS (EI) anal. calcd for C19H10N4O2 (M+): 326.0804. Found:
326.0802.

6-(Thiophen-2-yl)benzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione
(7g)
Brown solid (26 mg, 77%). Mp 268–269
°C. 1H NMR (500 MHz, DMSO-d6): δ 6.42 (dd, J = 7.7, 1.6 Hz, 1H), 6.69
(d, J = 10.3 Hz, 1H), 6.78 (d, J = 10.3 Hz, 1H), 7.13–7.16 (m, 1H), 7.18–7.22 (m, 1H),
7.44–7.49 (m, 2H), 7.55 (dd, J = 7.9, 1.3
Hz, 1H), 7.79–7.81 (m, 1H). 13C NMR (125 MHz, DMSO-d6): δ 124.3, 126.2, 127.8, 128.8, 129.0,
130.1, 132.1, 133.0, 133.4, 133.8, 135.3, 137.5, 142.0, 146.7, 151.9,
163.3, 177.5, 180.6. HRMS (EI) anal. calcd for C18H9N3O2S (M+): 331.0415. Found:
331.0416.

1,2,3,4-Tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione
(7h)
Brown solid (21 mg, 81%). Mp 215–217
°C. 1H NMR (500 MHz, DMSO-d6): δ 1.90–2.00 (m, 4H), 2.90–2.93 (m, 2H), 3.14–3.16
(m, 2H), 6.72 (d, J = 10.3 Hz, 1H), 6.83 (d, J = 10.3 Hz, 1H), 9.58 (s, 1H). 13C NMR (125
MHz, DMSO-d6): δ 22.6, 23.6, 24.3,
32.3, 119.0, 120.6, 137.6, 139.5, 144.0, 146.4, 148.5, 150.6, 180.8,
181.3. HRMS (EI) anal. calcd for C14H11N3O2 (M+): 253.0851. Found: 253.0854.

6-Methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione (7i)
Brown solid (23
mg, 87%). Mp 197–200 °C. 1H NMR (500 MHz, DMSO-d6): δ 1.55 (s, 3H), 1.77–1.92 (m,
4H), 2.90–2.94 (m, 2H), 2.98–3.00 (m, 2H), 6.95 (d, J = 10.4 Hz, 1H), 7.01 (d, J = 10.4 Hz,
1H). 13C NMR (125 MHz, DMSO-d6): δ 21.0, 21.2, 21.5, 25.0, 32.7, 123.4, 129.6, 132.5, 136.0,
137.0, 143.6, 148.9, 166.5, 176.0, 181.8. HRMS (EI) anal. calcd for
C15H13N3O2 (M+): 267.1008. Found: 267.1007.

6-Phenyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione (7j)
Brown
solid (27
mg, 83%). Mp 233–235 °C. 1H NMR (500 MHz, DMSO-d6): δ 1.77–1.82 (m, 2H), 1.87–1.92
(m, 2H), 2.90–2.94 (m, 2H), 2.98–3.00 (m, 2H), 6.84
(d, J = 10.4 Hz, 1H), 6.90 (d, J = 10.4 Hz, 1H), 7.31–7.32 (m, 2H), 7.51–7.53 (m, 3H). 13C NMR (125 MHz, DMSO-d6): δ
20.7, 20.9, 24.7, 32.4, 123.1. 126.3, 128.2, 128.4, 129.8, 132.2,
135.7, 136.7, 139.2, 143.3, 148.6, 166.2, 175.7, 181.5. HRMS (EI)
anal. calcd for C20H15N3O2 (M+): 329.1164. Found: 329.1162.

6-Benzyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione (7k)
Brown
solid (27
mg, 80%). Mp 219–222 °C. 1H NMR (500 MHz, DMSO-d6): δ 1.90–1.98 (m, 4H), 2.88–2.91
(m, 2H), 3.12–3.14 (m, 2H), 3.92 (s, 2H), 6.81 (d, J = 10.4 Hz, 1H), 6.87 (d, J = 10.4 Hz,
1H), 7.24–7.27 (m, 1H), 7.31–7.34 (m, 2H), 7.66–7.69
(m, 2H). 13C NMR (125 MHz, DMSO-d6): δ 22.2, 23.0, 23.7, 31.6, 42.0, 115.2, 118.0, 126.4,
127.6, 128.0, 128.5, 129.4, 134.9, 145.5, 148.6, 150.3, 150.4, 176.9,
179.5. HRMS (EI) anal. calcd for C21H17N3O2 (M+): 343.1321. Found: 343.1322.

6-Propyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione (7l)
Brown solid (24
mg, 80%). Mp 208–210 °C. 1H NMR (500 MHz, DMSO-d6): δ 0.83–0.86 (m, 3H), 1.77–1.82
(m, 2H), 1.87–1.92 (m, 2H), 1.98–2.06 (m, 2H), 2.35–2.38
(m, 2H), 2.90–2.92 (m, 2H), 2.98–3.00 (m, 2H), 6.81
(d, J = 10.4 Hz, 1H), 6.87 (d, J = 10.4 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): δ 14.0, 19.1, 21.8, 22.0, 25.7, 33.4, 40.9,
124.2, 125.7, 133.3, 136.8, 137.8, 144.4, 149.7, 167.3, 176.8, 182.6.
HRMS (EI) anal. calcd for C17H17N3O2 (M+): 295.1321. Found: 295.1322.

2-Methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-c]quinazoline-8,11-dione (7m)
Brown
solid (20
mg, 76%). Mp 207–209 °C. 1H NMR (500 MHz, DMSO-d6): δ 1.12 (d, J = 6.6
Hz, 3H), 1.53–161 (m, 1H), 1.92–2.06 (m, 2H), 2.43–2.49
(m, 1H), 2.90–2.95 (m, 1H), 2.98–3.05 (m, 1H), 3.15–3.19
(m, 1H), 6.71 (d, J = 10.4 Hz, 1H), 6.77 (d, J = 10.4 Hz, 1H), 9.03 (s, 1H). 13C NMR (125
MHz, DMSO-d6): δ 21.1, 28.6, 30.3,
32.9, 34.3, 116.1, 117.1, 133.2, 136.5, 143.1, 145.3, 149.2, 165.3,
177.2, 180.7. HRMS (EI) anal. calcd for C15H13N3O2 (M+): 267.1008. Found: 267.1009.

2,3,4,5-Tetrahydro-1H-benzo[4,5]imidazo[1,2-c]cyclohepta[e]pyrimidine-9,12-dione (7n)
Brown solid (24 mg, 89%). Mp 216–218 °C. 1H NMR (500 MHz, DMSO-d6): δ
1.80–1.84 (m, 2H), 1.97–2.02 (m, 4H), 2.92–2.95
(m, 2H), 3.62–3.64 (m, 2H), 6.88 (d, J = 10.4
Hz, 1H), 6.94 (d, J = 10.4 Hz, 1H), 9.06 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ
24.1, 26.4, 29.7, 31.0, 33.0, 120.2, 123.2, 132.3, 135.8, 143.4, 148.7,
166.3, 175.8, 181.6. HRMS (EI) anal. calcd for C15H13N3O2 (M+): 267.1008. Found:
267.1009.

1,2,3,4,5,6-Hexahydrobenzo[4,5]imidazo[1,2-c]cycloocta[e]pyrimidine-10,13-dione (7o)
Brown solid (21 mg, 73%). Mp 229–231 °C. 1H NMR (500 MHz, DMSO-d6): δ
1.27–1.32 (m, 2H), 1.38–1.42 (m, 2H), 1.66–1.71
(m, 2H), 1.82–1.87 (m, 2H), 2.73–2.76 (m, 2H), 3.59–3.61
(m, 2H), 6.85 (d, J = 10.3 Hz, 1H), 6.89 (d, J = 10.3 Hz, 1H), 9.10 (s, 1H). 13C NMR (125
MHz, DMSO-d6): δ 24.7, 25.3, 27.7,
28.3, 28.9, 31.1, 122.9, 125.8, 133.6, 140.1, 146.3, 151.0, 151.6,
157.1, 174.0, 181.9. HRMS (EI) anal. calcd for C16H15N3O2 (M+): 281.1164. Found:
281.1162.

1,2,3,4,5,6,7,8,9,10-Decahydrobenzo[4,5]imidazo[1,2-c]cyclododeca[e]pyrimidine-14,17-dione
(7p)
Brown solid (24 mg, 70%). Mp 245–247
°C. 1H NMR (500 MHz, DMSO-d6): δ 1.29–1.39 (m, 8H), 1.43–1.53 (m, 4H), 1.56–1.61
(m, 2H), 1.70–1.76 (m, 2H), 2.82–2.85 (m, 2H), 3.57–3.60
(m, 2H), 6.85 (d, J = 10.3 Hz, 1H), 6.91 (d, J = 10.3 Hz, 1H), 9.30 (s, 1H). 13C NMR (125
MHz, DMSO-d6): δ 20.9, 21.2, 24.1,
24.4, 24.7, 25.0, 25.1, 25.3, 26.5, 28.1, 123.0, 124.9, 133.3, 139.7,
146.0, 150.4, 151.0, 157.8, 173.9, 181.5. HRMS (EI) anal. calcd for
C20H23N3O2 (M+): 337.1790. Found: 337.1792.

4-Methyl-3-phenylbenzo[4,5]imidazo[1,2-c]pyrimidine-6,9-dione
(7q)
Brown solid (21 mg, 73%). Mp 228–230
°C. 1H NMR (500 MHz, DMSO-d6): δ 2.17 (s, 3H), 6.56 (d, J = 10.4 Hz, 1H),
6.75 (d, J = 10.4 Hz, 1H), 7.47–7.50 (m, 3H),
7.51–7.54 (m, 2H), 9.42 (s, 1H). 13C NMR (125 MHz,
DMSO-d6): δ 14.6, 120.6, 122.1,
127.4, 127.5, 129.0, 131.9, 133.4, 138.3, 144.8, 145.9, 150.4, 157.5,
172.4, 181,4. HRMS (EI) anal. calcd for C17H11N3O2 (M+): 289.0851. Found: 289.0849.

3,4-Diphenylbenzo[4,5]imidazo[1,2-c]pyrimidine-6,9-dione
(7r)
Brown solid (25 mg, 71%). Mp 249–252
°C. 1H NMR (500 MHz, DMSO-d6): δ 6.74 (d, J = 10.2 Hz, 1H), 6.89 (d, J = 10.2 Hz, 1H), 7.24–7.27 (m, 2H), 7.29–7.31
(m, 2H), 7.33–7.36 (m, 6H), 9.11 (s, 1H). 13C NMR
(125 MHz, DMSO-d6): δ 120.7, 125.8,
127.5, 127.8, 128.1, 128.9, 129.0, 129.3, 134.2, 134.3, 136.1, 136.5,
136.7, 144.1, 148.5, 162.2, 176.0, 181.3. HRMS (EI) anal. calcd for
C22H13N3O2 (M+): 351.1008. Found: 351.1005.

Experimental Procedure
for Mechanism Study
A 5 mL microwave
reaction tube was charged with 8 (0.086 g, 0.3 mmol)
and 2 (0.073 g, 0.6 mmol), together with CuI (0.006 g,
0.03 mmol), l-proline (0.010 g, 0.09 mmol), Cs2CO3 (0.293 g, 0.9 mmol), and DMF (3 mL). The reaction
mixture was heated to 130 °C for 1 h by microwave irradiation
at 100 W initial power. The mixture was then cooled to room temperature
and filtered through a short silica gel column (ethyl acetate) to
remove inorganic components. Removal of the solvent left a crude mixture,
which was separated by TLC (dichloromethane/MeOH = 97:3) to give 9.

N-(2-(1-Methyl-1H-benzo[d]imidazol-2-yl)phenyl)benzamide (9)
Pale yellow solid (69 mg, 70%). Mp 267–269 °C. 1H NMR (500 MHz, CDCl3): δ 3.87 (s, 3H), 7.30–7.38
(m, 3H), 7.39–7.43 (m, 2H), 7.46–7.59 (m, 5H), 7.76–7.78
(m, 2H), 7.82–7.84 (m, 1H), 12.18 (s, 1H). 13C NMR
(125 MHz, CDCl3): δ 31.7, 109.6, 119.9, 122.5, 122.8,
123.0, 127.0, 127.5, 128.6, 128.7, 129.5, 129.7, 130.3, 131.3, 132.5,
136.6, 143.0, 153.8, 165.4. HRMS (EI) calcd for C21H17N3O (M+): 327.1372. Found: 327.1372.

Supporting Information Available
The Supporting Information
is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b00805.Copies of 1H and 13C NMR spectra
(PDF)



Supplementary Material
ao8b00805_si_001.pdf

 Author Present Address
† Department
of Chemistry, Kyungpook National University, 80 Daehakro,
Bukgu, Daegu 41566, Republic of Korea (S.L.H.).

The authors
declare no competing financial interest.

Acknowledgments
This study
was supported by Basic Science Research Program
through the National Research Foundation of Korea (NRF) funded by
the Ministry of Education (2017R1D1A1B03028226). P.D.Q.D. acknowledges
Y.M. Park Internal Medicine of Geoje Medical Center (Gyeongnam, Republic
of Korea) for partial financial support during his stay in the Republic
of Korea.
==== Refs
References
For recent reviews on copper-catalyzed synthesis
of N-heterocyclic compounds:

a Guo X.-X. ; Gu D.-W. ; Wu Z. ; Zhang W. 
Chem.
Rev. 
2015 , 115 , 1622 –1651 . 10.1021/cr500410y .25531056  b Liu T. ; Fu H. 
Synthesis 
2012 , 44 , 2805 –2824 . 10.1055/s-0032-1316763 . c Liu Y. ; Wan J.-P. 
Org. Biomol. Chem. 
2011 , 9 , 6873 –6894 . 10.1039/c1ob05769c .21879127 
For synthetic methods and
biological activities
of benzo[4,5]imidazo[1,2-c]pyrimidines:

a Tardy S. ; Orsato A. ; Mologni L. ; Bisson W. H. ; Donadoni C. ; Gambacorti-Passerini C. ; Scapozza L. ; Gueyrard D. ; Goekjian P. G. 
Bioorg. Med. Chem. 
2014 , 22 , 1303 –1312 . 10.1016/j.bmc.2014.01.007 .24468632  b Hammad M. A. ; Nawwar G. A. M. ; Elgemeie G. E. H. ; Elnagdi M. H. 
Heterocycles 
1985 , 23 , 2177 –2181 . 10.3987/R-1985-09-2177 .
For synthetic methods and biological
activities
of benzo[4,5]imidazo[1,2-c]quinazolines:

a Shinde A. H. ; Arepally S. ; Baravkar M. D. ; Sharada D. S. 
J. Org. Chem. 
2017 , 82 , 331 –342 . 10.1021/acs.joc.6b02423 .27936770  b Ahmadi F. ; Bazgir A. 
RSC Adv. 
2016 , 6 , 61955 –16958 . 10.1039/C6RA06828F . c Shen C. ; Wang L. ; Wen M. ; Shen H. ; Jin J. ; Zhang P. 
Ind. Eng. Chem. Res. 
2016 , 55 , 3177 –3181 . 10.1021/acs.iecr.5b04452 . d Rai B. ; Kumar P. ; Kumar A. 
RSC Adv. 
2015 , 5 , 85915 –85918 . 10.1039/C5RA15525H . e Liu Q. ; Yang H. ; Jiang Y. ; Zhao Y. ; Fu H. 
RSC Adv. 
2013 , 3 , 15636 –15644 . 10.1039/c3ra41644e . f Sang P. ; Xie Y. ; Zou J. ; Zhang Y. 
Org. Lett. 
2012 , 14 , 3894 –3897 . 10.1021/ol3016435 .22793993  g Xu S. ; Lu J. ; Fu H. 
Chem. Commun. 
2011 , 47 , 5596 –5598 . 10.1039/c1cc10383k . h Rohini R. ; Shanker K. ; Reddy P. M. ; Ho Y.-P. ; Ravinder V. 
Eur. J. Med. Chem. 
2009 , 44 , 3330 –3339 . 10.1016/j.ejmech.2009.03.022 .19371978  i Galarce G. D. ; Foncea R. E. ; Edwards A. M. ; Pessoa-Mahana H. ; Pessoa-Mahana C. D. ; Ebensperger R. A. 
Biol. Res. 
2008 , 41 , 43 –50 . 10.4067/S0716-97602008000100006 .18769762 
Dao P. D. Q. ; Lee H. K. ; Sohn H.-S. ; Yoon N. S. ; Cho C. S. 
ACS Omega 
2017 , 2 , 2953 –2958 . 10.1021/acsomega.7b00693 .31457630 
For copper-catalyzed
C-N coupling of amides with vinyl halides: Jiang L. ; Job G. E. ; Klapars A. ; Buchwald S. L. 
Org. Lett. 
2003 , 5 , 3667 –3669 . 10.1021/ol035355c .14507200 
Nandwana N. K. ; Pericherla K. ; Kaswan P. ; Kumar A. 
Org. Biomol. Chem. 
2015 , 13 , 2947 –2950 . 10.1039/C4OB02375G .25612268 
Xu L. ; Jiang Y. ; Ma D. 
Org. Lett. 
2012 , 14 , 1150 –1153 . 10.1021/ol300084v .22313025 
Nandwana N. K. ; Dhiman S. ; Shelke G. M. ; Kumar A. 
Org. Biomol. Chem. 
2016 , 14 , 1736 –1741 . 10.1039/C5OB02469B .26732527 
a Ho S. L. ; Dao P. D. Q. ; Cho C. S. 
Synlett 
2017 , 28 , 1811 –1815 . 10.1055/s-0036-1588834 . b Yang B. W. ; Dao P. D. Q. ; Yoon N. S. ; Cho C. S. 
J. Organomet. Chem. 
2017 , 851 , 136 –142 . 10.1016/j.jorganchem.2017.09.025 . c Yoo J. M. ; Ho S. L. ; Cho C. S. 
Synlett 
2016 , 27 , 1383 –1386 . 10.1055/s-0035-1561560 . d Yang B. W. ; Ho S. L. ; Lim H.-J. ; Cho C. S. 
J. Organomet. Chem. 
2016 , 806 , 83 –87 . 10.1016/j.jorganchem.2015.12.040 .
Batenko N. ; Kricka A. ; Belyakov S. ; Turovska B. ; Valters R. 
Tetrahedron Lett. 
2016 , 57 , 292 –295 . 10.1016/j.tetlet.2015.12.002 .
a Moriarty E. ; Aldabbagh F. 
Tetrahedron Lett. 
2009 , 50 , 5251 –5253 . 10.1016/j.tetlet.2009.07.023 . b Hehir S. ; O’Donovan L. ; Carty M. P. ; Aldabbagh F. 
Tetrahedron 
2008 , 64 , 4196 –4203 . 10.1016/j.tet.2008.02.093 . c Lynch M. ; Hehir S. ; Kavanagh P. ; Leech D. ; O’Shaughnessy J. ; Carty M. P. ; Aldabbagh F. 
Chem. - Eur. J. 
2007 , 13 , 3218 –3226 . 10.1002/chem.200601450 .17200920  d Aldabbagh F. ; O’Shaughnessy J. 
Synthesis 
2005 , 1069 –1076 . 10.1055/s-2005-861832 . e Skibo E. B. ; Islam I. ; Schulz W. G. ; Zhou R. ; Bess L. ; Boruah R. 
Synlett 
1996 , 297 –309 . 10.1055/s-1996-5399 .
a Gellis A. ; Kovacic H. ; Boufatah N. ; Vanelle P. 
Eur. J. Med. Chem. 
2008 , 43 , 1858 –1864 . 10.1016/j.ejmech.2007.11.020 .18222567  b O’Donovan L. ; Carty M. P. ; Aldabbagh F. 
Chem. Commun. 
2008 , 5592 –5594 . 10.1039/b814706j . c Newsome J. J. ; Colucci M. A. ; Hassani M. ; Beall H. D. ; Moody C. J. 
Org. Biomol. Chem. 
2007 , 5 , 3665 –3673 . 10.1039/b713044a .17971996  d Lavergne O. ; Fernandes A.-C. ; Bréhu L. ; Sidhu A. ; Brézak M.-C. ; Prévost G. ; Ducommun B. ; Contour-Galcera M.-O. 
Bioorg. Med. Chem. Lett. 
2006 , 16 , 171 –175 . 10.1016/j.bmcl.2005.09.030 .16216500  e Baraldi P. G. ; Bovero A. ; Fruttarolo F. ; Preti D. ; Tabrizi M. A. ; Pavani M. G. ; Romagnoli R. 
Med. Res. Rev. 
2004 , 24 , 475 –528 . 10.1002/med.20000 .15170593  f Garuti L. ; Roberti M. ; Pizzirani D. ; Pession A. ; Leoncini E. ; Cenci V. ; Hrelia S. 
Farmaco 
2004 , 59 , 663 –668 . 10.1016/j.farmac.2004.04.001 .15262537 
a Ho S. L. ; Cho C. S. ; Sohn H.-S. 
Synthesis 
2015 , 47 , 216 –220 . 10.1055/s-0034-1379103 . b Ho S. L. ; Yoon I. C. ; Cho C. S. ; Choi H.-J. 
J. Organomet.
Chem. 
2015 , 791 , 13 –17 . 10.1016/j.jorganchem.2015.05.040 .
a Jardim G. A.
M. ; Bower J. F. ; da Silva
Júnior E. N. 
Org. Lett. 
2016 , 18 , 4454 –4457 . 10.1021/acs.orglett.6b01586 .27599589  b Sanna V. ; Nurra S. ; Pala N. ; Marceddu S. ; Pathania D. ; Neamati N. ; Sechi M. 
J. Med. Chem. 
2016 , 59 , 5209 –5220 . 10.1021/acs.jmedchem.5b01571 .27139920 
HBr/FeCl3 oxidation
system can
be used alternatively. However, for example, lower yield (74%) of 7a was observed.

a Moriarty E. ; Carr M. ; Bonham S. ; Carty M. P. ; Aldabbagh F. 
Eur. J. Med. Chem. 
2010 , 45 , 3762 –3769 . 10.1016/j.ejmech.2010.05.025 .20605274  b Alvarez F. ; Ghérardi A. ; Nebois P. ; Sarciron M.-E. ; Pétavy A.-F. ; Walchshofer N. 
Bioorg. Med. Chem. Lett. 
2002 , 12 , 977 –979 . 10.1016/S0960-894X(02)00064-1 .11959007 
Scale-up experiment: similar treatment
of 4a (1.666 g, 5 mmol) with 2a (0.450 g,
10 mmol)
in the presence of CuI (1 mmol) and K2CO3 (15
mmol) in DMF (15 mL) at 130 °C for 24 h afforded 5a in 72% yield. 5a (1.006 g, 3.6 mmol) was converted
into 7a in 84% yield under CAN (14.4 mmol).


a Hassan J. ; Sévignon M. ; Gozzi C. ; Schulz E. ; Lemaire M. 
Chem. Rev. 
2002 , 102 , 1359 –1470 . 10.1021/cr000664r .11996540  b Beletskaya I. P. ; Cheprakov A. V. 
Coord. Chem. Rev. 
2004 , 248 , 2337 –2364 . 10.1016/j.ccr.2004.09.014 .
a Song B. ; Knauber T. ; Gooβen L. J. 
Angew. Chem.,
Int. Ed. 
2013 , 52 , 2954 –2958 . 10.1002/anie.201208025 . b Chung K. H. ; So C. C. ; Wong S. M. ; Luk C. H. ; Zhou Z. ; Lau C. P. ; Kwong F. Y. 
Chem. Commun. 
2012 , 48 , 1967 –1969 . 10.1039/c2cc15972d .
Davoodnia A. 
Asian J. Chem. 
2010 , 22 , 1591 –1594 .

